EUVIMEDEUVIMED entdecken
Crossref

Astragaloside IV regulates macrophage polarization via the TLR4/NF-κB/STAT3 pathway to inhibit the malignant phenotype of renal clear cell carcinoma

Zhanshi Wang, Chao Feng, Guodong Chen, Qi Cai

Naunyn-Schmiedeberg's Archives of Pharmacology · 2025

DOI: 10.1007/s00210-025-04219-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Zhanshi Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou City, Zhejiang Province, 330012, China. Hauptthemen laut MEDLINE: Saponins, Carcinoma, Renal Cell, Triterpenes, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is a common and aggressive type of kidney cancer. This study aimed to investigate the effect of astragaloside IV (AS-IV) on ccRCC. A variety of cell experimental techniques were used, inducing macrophage polarization, and detecting relevant indicators by flow cytometry, qRT-PCR, immunofluorescence, MTT, wound healing, Transwell, and western blot. A nude mouse xenograft tumor model was constructed for in vivo studies, and siRNA interference technology was used to explore the signaling pathway. The results demonstrated successful macrophage polarization, with AS-IV inhibiting M2 macrophage polarization and promoting the transition from M0 to M1 polarization. Additionally, AS-IV suppressed ccRCC cell proliferation, migration, and invasion, while reversing the malignant effects of M2 macrophages. The study further revealed that AS-IV inhibited M2 polarization through the TLR4/NF-κB/STAT3 signaling pathway. In vivo experiments showed that AS-IV inhibited the growth of ccRCC tumors. This study revealed that AS-IV influences macrophage polarization by regulating the TLR4/NF-κB/STAT3 signaling pathway, thereby inhibiting the malignant phenotype of ccRCC. This finding provides new insights and potential therapeutic strategies for the treatment of ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SaponinsCarcinoma, Renal CellTriterpenesKidney NeoplasmsMacrophagesAntineoplastic Agents, PhytogenicAnimalsToll-Like Receptor 4HumansSTAT3 Transcription FactorNF-kappa BMice, NudeSignal TransductionMiceCell Line, TumorMice, Inbred BALB CCell ProliferationPhenotypeXenograft Model Antitumor AssaysCell MovementMale

Stichwörter der Autor:innen

Astragaloside IVMacrophage polarizationRenal clear cell carcinomaTLR4/NF-κB/STAT3

Substanzen

SaponinsTriterpenesastragaloside AToll-Like Receptor 4STAT3 Transcription FactorNF-kappa BTLR4 protein, humanSTAT3 protein, humanAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Urology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou City, Zhejiang Province, 330012, China.
  • Department of Urology, Tongde Hospital of Zhejiang Province, No. 234 Gucui Road, Xihu District, Hangzhou City, Zhejiang Province, 330012, China. caiqi423@163.com.

Zitieren

APA

Wang, Z., Feng, C., Chen, G., & Cai, Q. (2025). Astragaloside IV regulates macrophage polarization via the TLR4/NF-κB/STAT3 pathway to inhibit the malignant phenotype of renal clear cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04219-3

Vancouver

Wang Z, Feng C, Chen G, Cai Q. Astragaloside IV regulates macrophage polarization via the TLR4/NF-κB/STAT3 pathway to inhibit the malignant phenotype of renal clear cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04219-3

BibTeX
@article{Wang2025,
  author = {Wang, Zhanshi and Feng, Chao and Chen, Guodong and Cai, Qi},
  title = {Astragaloside IV regulates macrophage polarization via the TLR4/NF-κB/STAT3 pathway to inhibit the malignant phenotype of renal clear cell carcinoma},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2025},
  doi = {10.1007/s00210-025-04219-3}
}
Kostenlos starten →